Joerg Bomke

Title: Joerg Bomke: Innovator in Biomarkers and PI3 Kinase Inhibitors

Introduction

Joerg Bomke is a prominent inventor based in Heidelberg, Germany. He has made significant contributions to the field of biochemistry, particularly in the development of biomarkers and inhibitors for various diseases. With a total of 3 patents, his work has the potential to impact medical treatments and diagnostics.

Latest Patents

Bomke's latest patents include innovative methods for utilizing EEF1A as a biomarker and screening MetAP2 inhibitors. The first patent describes a method for screening compounds that inhibit MetAP2 activity by using a cellular system capable of expressing MetAP2 and/or EEF1A. This method involves incubating the system with compounds and detecting MetAP2 inhibition through the determination of EEF1A with an N-terminal methionine residue. Additionally, this invention provides a method for monitoring physiological and pathological conditions related to MetAP2 activity by administering compounds to mammals and analyzing biological samples for MetEEF1A. His second patent focuses on pyridinylimidazolone derivatives as PI3K inhibitors, which can be used to treat autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases, and tumors.

Career Highlights

Joerg Bomke is currently associated with Merck Patent GmbH, where he continues to advance his research and development efforts. His work is characterized by a strong focus on innovative solutions that address critical health challenges.

Collaborations

Bomke has collaborated with notable colleagues, including Ulrich Emde and Hans Peter Buchstaller, to further enhance the impact of his research.

Conclusion

Joerg Bomke's contributions to the fields of biomarkers and PI3 kinase inhibitors demonstrate his commitment to advancing medical science. His innovative patents reflect a dedication to improving treatment options for various diseases.